Unknown

Dataset Information

0

Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.

ABSTRACT:

SUBMITTER: Horby P 

PROVIDER: S-EPMC8298006 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.

Horby Peter P   Staplin Natalie N   Haynes Richard R   Landray Martin M  

Lancet (London, England) 20210701 10297

Similar Datasets

Unknown Tocilizumab for severe COVID-19 pneumonia - Authors' reply.
| S-EPMC7431126 | biostudies-literature
Unknown Tocilizumab in COVID-19: finding the optimal route and dose - Authors' reply.
| S-EPMC7498220 | biostudies-literature
Unknown Cancer and COVID-19 - Authors' reply.
| S-EPMC7544437 | biostudies-literature
Unknown Authors' reply: Hypoalbuminemia in COVID-19.
| S-EPMC8662292 | biostudies-literature
Unknown COVID-19 in pregnant women - Authors' reply.
| S-EPMC7195406 | biostudies-literature
Unknown Mavrilimumab for severe COVID-19 - Authors' reply.
| S-EPMC7837188 | biostudies-literature
Unknown Tocilizumab in COVID-19 therapy: who benefits, and how?
| S-EPMC8298010 | biostudies-literature
Unknown Surgery during the COVID-19 pandemic - Authors' reply.
| S-EPMC7833325 | biostudies-literature
Unknown Depression and anxiety during COVID-19 - Authors' reply.
| S-EPMC8813062 | biostudies-literature
Unknown Baricitinib for COVID-19: a suitable treatment? - Authors' reply.
| S-EPMC7271155 | biostudies-literature